2019
Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2016
Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings
Verplaetse TL, McKee SA. Targeting the Brain Stress Systems for the Treatment of Tobacco/Nicotine Dependence: Translating Preclinical and Clinical Findings. Current Addiction Reports 2016, 3: 314-322. PMID: 31275802, PMCID: PMC6609087, DOI: 10.1007/s40429-016-0115-x.Peer-Reviewed Original ResearchBrain stress systemsTobacco useNoradrenergic systemTreatment strategiesCorticotropin-releasing factor (CRF) systemTobacco/nicotine dependenceMajority of smokersNicotine-induced activationPotential treatment strategySmoking-related outcomesNicotine-motivated behaviorsLong-term abstinenceStress systemClinical findingsAdrenal axisTobacco dependencePreventable mortalityClinical investigationNicotine dependenceRecent FindingsOneTherapeutic benefitPharmacological agentsCRF systemDrug AdministrationSummaryThis review
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen